IRES: Cross-disciplinary Computational Biology Training Read more about IRES: Cross-disciplinary Computational Biology Training
Safety and Efficacy of GEN3009 (DuoHexaBody-CD37) in Relapsed or Refractory B-cell Non-Hodgkin Lymphoma a First-in-Human, Open-label, Phase I/IIa Dose Escalation Trial with Dose Expansion Cohorts Read more about Safety and Efficacy of GEN3009 (DuoHexaBody-CD37) in Relapsed or Refractory B-cell Non-Hodgkin Lymphoma a First-in-Human, Open-label, Phase I/IIa Dose Escalation Trial with Dose Expansion Cohorts
STROKE - Suspected Emergent Stroke Detection with EEG Read more about STROKE - Suspected Emergent Stroke Detection with EEG
Randomized, Open-Label Study of the BRIA-IMT Regimen and Check Point Inhibitor vs Physician's Choice in Advanced Metastatic Breast Cancer (BRIA-ABC) Read more about Randomized, Open-Label Study of the BRIA-IMT Regimen and Check Point Inhibitor vs Physician's Choice in Advanced Metastatic Breast Cancer (BRIA-ABC)
ROWAN: An Open-Label, Prospective, Multi-Center Clinical Trial to Evaluate the Efficacy and Safety of TheraSphere? Followed by Durvalumab (Imfinzi?) with Tremelimumab (Imjudo?) for Hepatocellular Carc Read more about ROWAN: An Open-Label, Prospective, Multi-Center Clinical Trial to Evaluate the Efficacy and Safety of TheraSphere? Followed by Durvalumab (Imfinzi?) with Tremelimumab (Imjudo?) for Hepatocellular Carc
A Randomized, Double-Blind, Placebo-Controlled, 2-Arm Phase III Study To Assess Efficacy and Safety of Xevinapant and Radiotherapy Compared to Placebo and Radiotherapy for Demonstrating Improvement of Read more about A Randomized, Double-Blind, Placebo-Controlled, 2-Arm Phase III Study To Assess Efficacy and Safety of Xevinapant and Radiotherapy Compared to Placebo and Radiotherapy for Demonstrating Improvement of
A Phase 3, Double-Blind, Randomized, Placebo-Controlled Study of Levosimendan in Pulmonary Hypertension Patients With Heart Failure With Preserved Left Ventricular Ejection Fraction (PH-HFpEF) Read more about A Phase 3, Double-Blind, Randomized, Placebo-Controlled Study of Levosimendan in Pulmonary Hypertension Patients With Heart Failure With Preserved Left Ventricular Ejection Fraction (PH-HFpEF)
A Phase 2/3, Randomized, Double-Blind, Controlled Study of Zamalintinib (XL092) in Combination with Pembrolizumab Vs Pembrolizumab in the First-Line Treatment of Subjects with Pd-LI Positive Recurrent Read more about A Phase 2/3, Randomized, Double-Blind, Controlled Study of Zamalintinib (XL092) in Combination with Pembrolizumab Vs Pembrolizumab in the First-Line Treatment of Subjects with Pd-LI Positive Recurrent
